Current Status of BTKi Treatment for CLL/SLL in China
Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors
The First Affiliated Hospital with Nanjing Medical University
1,000 participants
Jul 13, 2024
OBSERVATIONAL
Conditions
Summary
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Eligibility
Inclusion Criteria3
- Age ≥ 18 years;
- Patients with a confirmed diagnosis of CLL/SLL;
- Received BTK inhibitor treatment between February 2023 and February 2024.
Exclusion Criteria2
- Patients with other types of lymphoma;
- Cases deemed unsuitable for inclusion in this study by the investigators.
Interventions
BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06508684